文献速递泌尿男性生殖肿瘤

二甲双胍在低危前列腺癌主动监测中的随机对照试验

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2025-10-30

MAST 为多中心、随机、双盲、安慰剂对照 III 期试验,评估二甲双胍能否延缓低危局限前列腺癌主动监测患者的疾病进展。共 408 例随机分组,中位随访 36 个月,二甲双胍组与安慰剂组无进展生存无显著差异,肥胖患者中二甲双胍与病理进展增加相关。

要点

  • 二甲双胍未显著改善低危前列腺癌主动监测患者的无进展生存。
  • 36 个月阴性活检率二甲双胍组 41.0% 对安慰剂组 31.1%,差异无统计学意义。
  • 肥胖(BMI≥30)患者中二甲双胍与病理进展增加相关,需进一步研究。

核心结论

  • 二甲双胍未减少低危前列腺癌主动监测患者的疾病进展。
  • 肥胖患者中观察到的病理进展增加效应值得进一步研究。

研究设计与样本

  • MAST 为多中心、随机、双盲、安慰剂对照 III 期试验。
  • 纳入低危局限前列腺癌并接受主动监测的男性,1:1 随机接受二甲双胍 850 mg 每日两次或安慰剂,随访至 36 个月。
  • 共 408 例随机分组(二甲双胍 205 例,安慰剂 203 例)。
  • 主要终点为至进展时间,定义为治疗和/或病理进展。

主要发现

  • 中位随访 36 个月,共 144 例发生进展(二甲双胍 70 例,安慰剂 74 例)。

临床怎么用

  • 不推荐使用二甲双胍来延缓低危前列腺癌主动监测患者的疾病进展。
  • 对肥胖(BMI≥30)低危前列腺癌患者使用二甲双胍需谨慎,并关注病理进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progression. Metformin, a commonly prescribed antidiabetic agent, has demonstrated antitumor activity in preclinical studies and observational data, prompting investigation into its potential to delay PCa progression. PATIENTS AND METHODS: The Metformin Active Surveillance Trial (MAST) was a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of metformin in men with low-risk, localized PCa managed with AS. Eligible participants were randomly assigned 1:1 to receive either metformin (850 mg twice daily) or placebo and were followed for up to 36 months. The primary end point was time to progression, defined as therapeutic and/or pathologic progression. Progression-free survival (PFS) was assessed using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: A total of 408 patients were randomly assigned (205 metformin, 203 placebo). After a median follow-up of 36 months, 144 participants experienced progression (70 metformin, 74 placebo), with no significant difference in PFS (hazard ratio [HR], 1.09 [95% CI, 0.79 to 1.52]; P = .59). Negative biopsy rates at 36 months were 41.0% (metformin) versus 31.1% (placebo; P = .181). In prespecified subgroup analysis, metformin was associated with increased pathologic progression among obese patients (BMI ≥ 30; HR, 2.36 [95% CI, 1.21 to 4.59]; P = .0092). CONCLUSION: Metformin did not reduce progression in men with low-risk PCa on AS. The observed adverse effect in obese patients merits further investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fleshner NE, Bernardino RM, Izawa J, et al. Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. J Clin Oncol. 2025. PMID: 41166665. doi:10.1200/JCO-25-01070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。